Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital

World Journal of Gastroenterology

Volumn 14, Issue 20, 2008, Pages 3201-3206

  Tolentino, Yolanda Faia Manhães ^a   Fogaça, Homero Soares ^a   Zaltman, Cyrla ^a   Ximenes, Lia Laura Lewis ^b   Coelho, Henrique Sérgio Moraes ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Hepatitis B virus; Inflammatory bowel disease; Prevalence; Risk factors

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; ILLICIT DRUG; IMMUNOSUPPRESSIVE AGENT; STEROID; VIRUS DNA;

ACUPUNCTURE; ADULT; ARTICLE; BLOOD TRANSFUSION; BODY PIERCING; BRAZIL; COLONOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIALYSIS; ENTERITIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEXUAL INTERCOURSE; SIGMOIDOSCOPY; TATTOOING; UNIVERSITY HOSPITAL; VIRUS TRANSMISSION;

EID: 48949099168     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3201     Document Type: Article

References (30)

1. World Health Organization. Hepatitis B. World Health Organization, 2000: 204
2. Kim WR, Benson JT, Therneau TM, Torgerson HA, Yawn BP, Melton LJ 3rd. Changing epidemiology of hepatitis B in a U.S. community. Hepatology 2004; 39: 811-816
3. D'Amelio R, Matricardi PM, Biselli R, Stroffolini T, Mele A, Spada E, Chionne P, Rapicetta M, Ferrigno, L, Pasquini P. Changing epidemiology of hepatitis B in Italy: public health implications. Am J Epidemiol 1992; 135: 1012-1018
4. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366
5. Chan HL, Ghany MG, Lok ASR Hepatitis B. In: Schiff ER, Sorell MF, Maddrey WC editors. Diseases of the liver. 8th ed. Philadelphia: Lippincott William & Wilkins, 1999: 758-791
6. Lok ASF, Chan HL. Viral Hepatitis B and D. In: O'Grady IG, Lake JR, Howdle PD editors. Comprehensive Clinical Hepatology. 1st ed. London: Mosby, 2000: 12.1-12.10
7. Nishioka Sde A, Gyorkos TW, MacLean JD. Tattoos and transfusion-transmitted disease risk: implications for the screening of blood donors in Brazil. Braz J Infect Dis 2002; 6: 172-180
8. Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994; 35: 84-89
9. Gaeta GB, Stroffolini T, Taliani G, Ippolito FM, Giusti G, De Bac C. Surgical procedures as a major risk factor for chronic hepatitis C virus infection in Italy: evidence from a case-control study. Int J Infect Dis 1999; 3: 207-210
10. Pallone F, Boirivant M, Stazi MA, Cosintino R, Prantera C, Torsoli A. Analysis of clinical course of postoperative recurrence in Crohn's disease of distal ileum. Dig Dis Sci 1992; 37: 215-219
11. Biancone L, Pavia M, Del Vecchio Blanco G, D'Inca R, Castiglione F, De Nigris F, Doldc, P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001; 7: 287-294
12. Biancone L, Del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002; 122: 593-594
13. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022
14. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495
15. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM. A randomidzed, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301
16. Froio N, Nicastri E, Comandini UV, Cherubini C, Felicioni R, Solmone M, Di Giulio S, Petrosillo N. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis 2003; 42: 546-550
17. Freeman R. Barriers to accessing and accepting dental care. Br Dent J 1999; 187: 81-84
18. Secretaria do Estado de Saúde do Rio de Janeiro-Assessoria de Doenças Transmissíveis por Sangae e Hemoderivados. Hepatites. Virais-9° Boletim Informativo, 2005
19. Spijkerman IJ, van Doorn LJ, Janssen MH, Wijkmans CJ, Bilkert-Mooiman MA, Coutinho RA, Weers-Pothoff G. Transmission of hepatitis B virus from a surgeon to his patients during high-risk and low-risk surgical procedures during 4 years. Infect Control Hosp Epidemiol 2002; 23: 306-312
20. Ishino Y, Ido K, Sugano K. Contamination with hepatitis B virus DNA in gastrointestinal endoscope channels: risk of infection on reuse after on-site cleaning. Endoscopy 2005; 37: 548-551
21. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 344: 1685-1690
22. Longo F, Hebuterne X, Tran A, Staccini P, Hastier P, Schneider S, Benzaken S, Tirtaine C, Rampal P. [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors] Gastroenterol Clin Biol 2000; 24: 77-81
23. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429
24. Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995; 27: 3-4
25. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365
26. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625
27. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107-109
28. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976
29. Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J Hepatol 2003; 39 Suppl 1: S206-S211
30. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749